Confronting the Challenge of Managing Moderate-to-Severe Atopic Dermatitis Web Activity

Chapter 1: Targeted Therapies for the Treatment of Moderate-to-Severe Atopic Dermatitis
Chapter 2: Managed Care Strategies to Enhance Outcomes in Atopic Dermatitis

Release Date: April 18, 2018
Expiration Date: October 31, 2019
Estimated Time to Complete Activity:

Chapter 1: 0.75 hour
Chapter 2: 0.75 hour

Compatible with all modern browsers and mobile devices

EXPERT FACULTY


	Jeffrey D. Dunn, PharmD, MBA Vice President, Clinical Strategy and Programs and Industry Relations MagellanRx Management Click here for biography

	Alan Menter, MD Chief, Division of Dermatology Baylor University Medical Center Click here for biography

	John Fox, MD, MHA Vice President, Associate Chief Medical Officer Medical Affairs Priority Health Click here for biography

TARGET AUDIENCE

Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for atopic dermatitis patients including: physicians, pharmacists, registered nurses, and case managers

STATEMENT OF NEED/PROGRAM OVERVIEW
Atopic dermatitis (AD), or eczema, is a common chronic, relapsing inflammatory skin disease marked by pruritus and skin irritation. It is associated with substantial morbidity and greatly impacts quality of life. Current prevalence is estimated to be 15%–30% among children and 2%–10% among adults, although its prevalence in adults may be underestimated. The majority (∼67%) of patients have mild disease and are adequately managed by their primary care provider (PCP). Patients with more difficult to treat disease are frequently referred to a dermatologist or other specialist. This activity is focused on AD diagnosis and treatment, impact of emerging AD therapies, adherence to therapy, and management of the pharmacy benefit.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

CHAPTER 1

Review recent insights into the pathophysiology of AD
Discuss the safety, efficacy, and attributes of emerging therapies for the treatment of AD

CHAPTER 2

Assess benefit design strategies to improve overall patient outcomes for AD
Align diagnosis and treatment strategies with evidence-based guidelines to optimize AD treatment outcomes
Apply methods to improve adherence to AD treatment

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Chapter 1: 0.75 CME credit
Chapter 2: 0.75 CME credit

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Chapter 1: UAN: JA4008162-9999-18-061-H01-P, 0.75 contact hour (knowledge)
Chapter 2: UAN: JA4008162-9999-18-073-H01-P, 0.75 contact hour (knowledge)

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours.

Chapter 1: 0.6 contact hour
Chapter 2: 0.7 contact hour

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Jeffrey D. Dunn, PharmD, MBA	Dr. Dunn has nothing to disclose.
Alan Menter, MD	Advisory Board for AbbVie, Inc., Allergan Pharmaceuticals, Amgen, Inc., Boehringer Ingleheim Pharmaceuticals, Inc., Eli-Lilly, Janssen Biotech, Inc., LEO Pharma, OrthoDermatologics, Promius Consulting fees from AbbVie, Inc., Afecta, Allergan Pharmaceuticals, Amgen Inc., Avillion, Eli-Lilly, Galderma, Janssen Biotech, Inc., LEO Pharma, Menlo, Novartis Pharmaceuticals Corporation, OrthoDermatologics, Promius, Pfizer,Inc., Vitae, Xenoport Investigator for AbbVie, Inc., Allergan Pharmaceuticals, Amgen, Inc., Anacor, Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Dermira, Eli-Lilly, Janssen Biotech, Inc., LEO Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron, Symbio / Maruho, Xenoport Speakers’ Bureau for AbbVie, Inc., Amgen, Janssen Biotech, Inc., Leo Pharma, OrthoDermatologics, Promius
John Fox, MD, MHA	Dr. Fox has nothing to disclose.

The PIM planners and managers have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period of April 18, 2018, through October 31, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.